Conclusions
Using a modified Delphi technique, we have defined a patient cohort with
CRSwNP where the BRS Council believe use of biologics are appropriate.
This group have higher rates of ‘failure’ with current treatment
pathways, higher resource use and are more likely to suffer with
uncontrolled symptoms. We would urge NICE to consider approval of
biologics for such indications without applying further restrictions on
use.
Ethical approval
There was no need for ethical approval for this study
Data availability
The results of scoring of the Delphi round may be made available to the
editorial team on request but it is not common practice to publish the
scores alongside the recommendations.